Piper Jaffray Cuts Price Target on Trovagene (TROV) Following 1Q Miss
Piper Jaffray maintained a Neutral rating on TrovaGene (NASDAQ: TROV), and cut the price target to $5.00 (from $8.00), following ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
